Interpretation of FDA's Guidance on Cybersecurity for Medical Devices (2025)

Inquiry

Background and Release Significance

In June 2025, the FDA released the latest version of "Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions", marking a new stage in the regulation of medical device cybersecurity.

The new version of the guideline is not merely a simple revision of the previous advisory document. Instead, it has strengthened the management of medical device products throughout their entire life cycle in response to increasingly serious cybersecurity threats, and clearly states that cybersecurity is an integral part of device safety.

The issue of cybersecurity is becoming increasingly serious

As medical devices gradually connect to the network, cloud, and the Internet of Things (IoT), the risk of being attacked by hackers has significantly increased. Cybersecurity vulnerabilities not only affect the normal operation of the devices but also pose a threat to the safety of patients.

Past ransomware incidents (such as the WannaCry attack in 2017) have proven the extensive impact of the lack of cybersecurity on medical facilities and equipment. The issue of cybersecurity is no longer a simple IT management problem; it is a key factor directly related to the safety of medical devices and patient safety.

Reasons for the release of the new guidelines

The background and purpose of the FDA's release of this guideline are very clear:

Responding to emerging threats

As the means of cyberattacks become increasingly complex, the existing compliance framework is unable to cover all the emerging cybersecurity challenges.

The complexity brought on by device interconnection

Medical devices are no longer isolated to individual devices but are widely connected to hospital networks, patients' personal devices, cloud platforms, and other multiple links, significantly increasing the attack surface.

Changes in international standards

Global medical device compliance standards are gradually strengthening cybersecurity requirements. This move by the FDA also responds to the relevant initiatives of the IMDRF, promoting a unified global regulatory standard.

Core Regulatory Logic

Cybersecurity is the safety of equipment

The new guidelines clearly state that cybersecurity is no longer an additional technical requirement, but rather an integral part of medical device design and quality. This viewpoint has profoundly influenced the research and development strategies and compliance paths of equipment manufacturers. Equipment applicants must consider and integrate security protection measures during the design stage, not only in the physical aspect, but also in the software, firmware, and operating system security design.

This approach by the FDA marks that cybersecurity requirements for medical devices are as important as traditional physical security requirements (such as biocompatibility, mechanical strength, etc.). This means that cybersecurity vulnerabilities are not only an issue for IT personnel, but also a critical link involving the core functions of medical devices.

Lifecycle-oriented security management

The TPLC safety management requirements proposed by the FDA require manufacturers to continuously manage and update network security, and cannot rely solely on pre-market tests.

Design stage

Ensure that the equipment follows safety best practices from the very beginning and implements SPDF.

Production and use stage

During production and use, the equipment must undergo real-time security detection, monitoring, and updates, and any discovered vulnerabilities must be promptly fixed.

Post-market stage

After the equipment is launched on the market, a sustainable patch update mechanism must be maintained to prevent known vulnerabilities from being exploited and to ensure the long-term network security of the equipment.

This life-cycle management thinking forces manufacturers to embed security design into product development from the very beginning, rather than resorting to remediation or solving problems through temporary fixes.

Transparency and responsibility allocation

The FDA's guidelines stipulate that the safety information on the equipment must be clear and transparent, ensuring that all users can understand the safety functions of the equipment and their respective responsibilities.

Equipment label requirements

Manufacturers are required to disclose on the labels the potential cybersecurity risks of the equipment, the allocation of responsibilities, and how to operate to minimize risks to the greatest extent.

Manufacturer responsibility

Equipment manufacturers must be responsible for the safety of the equipment, including firmware updates, vulnerability fixes, and compatibility testing with other systems.

User responsibility

Medical institutions and end-users also need to assume corresponding responsibilities, ensuring that the equipment operates in the correct environment and undergoes appropriate updates and management. This transparent division of responsibilities will make the entire medical device ecosystem safer and more reliable.

Main Requirements Analysis

Secure Product Development Framework (SPDF)

The guideline recommends that all medical device manufacturers adopt SPDF to manage the safety risks of their equipment. SPDF is not merely a technical process; it is also a company-wide management system that covers the following aspects.

Threat modeling

Identify various cybersecurity threats that the product may encounter during its lifecycle and analyze the potential risks.

Security architecture design

Ensure that the product design has the ability to resist known and unknown network attacks, including aspects such as encryption, authentication, and access control.

Security verification and testing

During the product design and development stages, thorough security verification and penetration testing must be conducted to ensure that the security design can be effectively implemented.

The implementation of this framework requires manufacturers to consider cybersecurity factors at every stage of product development, rather than just conducting one-time vulnerability detection before the product is launched.

Software Bill of Materials (SBOM)

The SBOM is formally introduced for the first time in the new guidelines and is required to be submitted to FDA as part of the pre-submission document.

The purpose of SBOM is to enhance the software transparency of the equipment, ensuring that manufacturers have comprehensive control and management capabilities over every software component used in the equipment, including third-party open-source components and commercial software.

Vulnerability response

The SBOM can help enterprises quickly locate the affected components when vulnerabilities are discovered and promptly release security updates.

Compliance requirements

According to the requirements of the guideline, the equipment must list all software components and provide detailed supply chain information, including the support lifecycle of the software suppliers, etc.

The introduction of SBOM is not only for compliance requirements, but also to improve the software management standards of the global medical device industry, promoting the entire industry towards transparency and traceability.

Security control measures and testing

The guideline details a number of security control measures (such as authentication, authorization, encryption, data integrity, event detection, etc.) and requires manufacturers to implement these controls in their designs and must pass verification tests to ensure they can effectively protect the equipment from network attacks.

Penetration testing and vulnerability scanning

Manufacturers are required to submit penetration testing reports and vulnerability scanning results to prove that the equipment can resist network attacks.

Fuzz testing and code audit

For the firmware and software within the equipment, deep fuzz testing and source code auditing must be conducted to identify potential security vulnerabilities.

These requirements mean that cybersecurity is no longer a "post-event repair" issue, but rather a comprehensive security protection system should be built at the product design stage.

Submission requirements for regulatory documents

The FDA has explicitly stipulated that in the pre-market submission documents, manufacturers are required to provide:

Safety architecture diagram

A diagram demonstrating how the equipment protects both the equipment and patient data through various safety controls.

Risk assessment report

Including an analysis of the safety and effectiveness of the equipment, especially an assessment of potential cybersecurity threats.

Security test report

The results of vulnerability scanning, penetration testing, static code analysis, etc. prove that the device's security meets the standards set by the FDA.

Impact on the Industries

Impact on equipment manufacturers

Cost and process changes

Equipment manufacturers will face higher R&D costs. In particular, they need to increase investment in cybersecurity, establish a professional security team, enhance compliance training, and purchase appropriate security testing tools, etc.

More importantly, manufacturers must gradually establish a cybersecurity risk assessment and control system during the product development process. This means that the development cycle and cost of equipment will increase.

New competitive barriers

From the perspective of market competition, companies that can meet the new regulations of the FDA will be able to gain higher market trust, especially on the global market. Companies that can promptly release security patches and manage the software supply chain of third parties will have more advantages in bidding and international markets.

Impact on hospitals and medical institutions

Hospitals and medical institutions will directly benefit from the implementation of the new FDA regulations. In the face of an increasingly complex cybersecurity environment, they will not only be the users of the equipment but also bear additional responsibilities such as equipment maintenance and vulnerability remediation.

Although this increases the pressure on their IT resources, it also helps to enhance the overall cybersecurity level of medical facilities.

Impact on the global industry

This new guideline will have a profound impact on the global medical device industry, particularly in Europe and China. With the successive introduction of regulations such as the EU MDR and the Chinese NMPA, the global medical device market is expected to converge towards a unified cybersecurity standard.

Global multinational companies will face more unified regulatory requirements, and these new standards will drive technological innovation and compliance processes in the global medical device industry.

Conclusions and Prospects

This new guideline marks that the medical device industry is entering the era of "cybersecurity as compliance".

The future regulatory trends will exhibit the following characteristics:

Regulation hardening

Cybersecurity will gradually be incorporated into mandatory regulations rather than being merely a guiding document.

Ecological transparency

SBOM promotes the transparency and collaboration of the global medical device supply chain.

Continuous regulation

Regulatory authorities not only focus on pre-market reviews but also strengthen post-market monitoring and compliance checks.

For enterprises, the challenge lies in investment and transformation, and the opportunity lies in leveraging compliance capabilities to establish new competitive advantages.

Disclaimer: The above content is compiled based on existing public information and is for reference only.

Our Services

Proregulations offers comprehensive FDA medical device cybersecurity compliance services to global medical device companies. By tailoring customized compliance strategies and implementation plans, it ensures that their products fully meet the latest regulatory requirements and enhances their competitiveness.

Regulatory interpretation and consultation
Customized training
Cybersecurity compliance strategy planning
Gap analysis
Preparation and Submission of Declaration Documents
Product Full Life Cycle Risk Management
FDA agent

Proregulations has always provided reliable and professional one-stop compliance solutions to accelerate the market launch of customers' medical devices, effectively reduce regulatory risks, and help enterprises achieve stable and sustainable development. If you are interested in our services, please contact us.

U.S. Medical Device 510(k) Premarket Notification